NCT06995651View on ClinicalTrials.gov

Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Pancreatic InsufficiencyCystic Fibrosis-related Diabetes
Interventions
DRUG

Dorzagliatin

Randomized, double-blind, cross-over study of Dorzagliatin 75 mg orally twice daily for 7 days compared to matched-placebo orally twice daily for 7 days.

DRUG

Placebo

Randomized, double-blind, cross-over study of Dorzagliatin 75 mg orally twice daily for 7 days compared to matched-placebo orally twice daily for 7 days.

Trial Locations (2)

19104

Hospital of University of Pennsylvania, Philadelphia

University of Pennsylvania Center for Human Phenomic Science (CHPS), Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER